Invitation to presentation of Clavis Pharma's third quarter results
2009
(Thomson Reuters ONE) - Clavis Pharma ASA (OSE: CLAVIS) releases the company's third quarter2009 results on Thursday 22 October 2009 at Hotel Continental,Stortingsgaten 24/26, Oslo, Norway.The presentation will start at 08:30 (CET).Following the presentation, there will be a Q&A session. Breakfastwill be served from 08:00 hours (CET). Clavis Pharma welcomes allinterested parties.The quarterly report and presentation will be available at the OsloStock Exchange, http://www.newsweb.no and Clavis Pharma's homepage,http://www.clavispharma.comContactGeir Christian Melen, CEOOffice : +47 24 11 09 65Mobile : +47 91 30 29 65E-mail : geir.christian.melen(at)clavispharma.comGunnar Manum, CFOOffice : +47 24 11 09 71Mobile : +47 95 17 91 90E-mail : gunnar.manum(at)clavispharma.comFor international press enquiries:Mark Swallow / Nina Enegren / David DibleCitigate Dewe RogersonOffice : +44 207 282 2948E-mail : clavispharma(at)citigatedr.co.ukAbout Clavis PharmaClavis Pharma ASA is an oncology focused pharmaceutical company usingits proprietary Lipid Vector Technology (LVT) platform to create NewChemical Entities (NCEs), by significantly improving alreadyestablished drugs. The improvements are achieved by chemicallybinding specific unsaturated lipids to existing, and well understood,approved pharmaceuticals. Data generated suggests the resultingpatentable NCEs offer improved efficacy and reduced side effectsthrough enhanced pharmacokinetic properties, greater tissuepenetration and, in many cases, additional modes of action.Clavis Pharma's objective is to develop its drug candidates untilsignificant value has been created and proof of principle in man hasbeen shown. For further clinical development and commercialisation ofthe products, Clavis Pharma will enter into strategic partnershipswith established pharmaceutical or biotech companies. The company'sproduct portfolio includes four new cancer drugs: Elacytarabine is inClinical Phase II, Intravenous CP-4126 is in Clinical Phase II, OralCP-4126 in Phase I, and CP-4200 is in preclinical development.Results indicate that these products have promising potential forseveral cancer indications within solid tumours and leukaemia.The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange(ticker: CLAVIS). Additional information on Clavis Pharma can befound at: http://www.clavispharma.com/.DisclaimerThe information contained herein shall not constitute an offer tosell or the solicitation of an offer to buy, nor shall there be anysale of the securities referred to herein in any jurisdiction inwhich such offer, solicitation or sale would be unlawful prior toregistration, exemption from registration or qualification under thesecurities laws of any such jurisdiction.This news release containsforward-looking statements and forecasts based on uncertainty, sincethey relate to events and depend on circumstances that will occur inthe future and which, by their nature, will have an impact on resultsof operations and the financial condition of Clavis Pharma. There area number of factors that could cause actual results and developmentsto differ materially from those expressed or implied by theseforward-looking statements. Theses factors include, among otherthings, risks associated with technological development, the riskthat research & development will not yield new products that achievecommercial success, the impact of competition, the ability to closeviable and profitable business deals, the risk of non-approval ofpatents not yet granted and difficulties of obtaining relevantgovernmental approvals for new products.No expressed or impliedrepresentations or warranties are given concerning Clavis Pharma orthe accuracy or completeness of the information or projectionsprovided herein, and no claims shall be made by the recipient hereofby virtue of this Information Memorandum or the information orprojections contained herein. Any representations or warranties madeto an investor in Clavis Pharma will be subject to separate sale andpurchase agreements to be negotiated between the parties.Clavis Pharma(TM) is a registered trademark of Clavis Pharma ASA.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 16.10.2009 - 09:33 Uhr
Sprache: Deutsch
News-ID 6991
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 230 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Invitation to presentation of Clavis Pharma's third quarter results
2009"
steht unter der journalistisch-redaktionellen Verantwortung von
Clavis Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
